Semax

Semax is a synthetic heptapeptide analogue of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-10) fragment. It is primarily researched for its potential cognitive-enhancing and neuroprotective properties. While structurally similar to a portion of ACTH, Semax lacks the steroidal effects associated with the full hormone. Its mechanism of action is complex and not fully elucidated, but research suggests it influences the expression of brain-derived neurotrophic factor (BDNF), a protein crucial for neuronal survival and plasticity. It is also believed to modulate the activity of enkephalins, endogenous opioid peptides involved in pain regulation and mood. Furthermore, studies indicate Semax may possess antioxidant properties and influence inflammatory responses within the brain.

The current research landscape surrounding Semax is largely preclinical, with a significant portion of studies conducted in vitro or using animal models. The available research papers, numbering over 200, explore a range of potential applications, including cognitive enhancement, neuroprotection against ischemic injury, and modulation of stress responses. For example, one study published in *Bioinorganic Chemistry and Applications* (cited 101 times) investigated Semax's ability to chelate copper and reduce copper-catalyzed reactive oxygen species (ROS) production, suggesting a potential role in mitigating the neurotoxic effects of amyloid-beta plaques associated with Alzheimer's disease. Another study in *ACS Chemical Neuroscience* (cited 88 times) examined Semax's impact on copper-induced amyloid-beta aggregation in artificial membrane models. Research published in *International Journal of Molecular Sciences* (cited 84 times) explored the antistress effects of melanocortin derivatives, including Semax, and their association with changes in gene expression in the hippocampus of rats subjected to acute stress. Further research in *Genes* (cited 80 times) investigated the impact of synthetic ACTH peptides on immune gene expression in the rat brain following stroke, and another *Genes* study (cited 71 times) looked at glyproline peptides' role in modulating inflammatory and neurosignaling genetic responses after cerebral ischemia-reperfusion. These studies, while promising, are primarily conducted in animal models and require further validation in human clinical trials.

The safety profile of Semax, based on available data, appears relatively benign. However, it is crucial to acknowledge the limited scope of human clinical trials. The FDA adverse event reporting system contains only two reports associated with Semax, neither of which were classified as serious. The reported reactions included dyspnoea, electrocardiogram QT prolongation, eye pain, a product advertising issue, and somnolence. It is important to note that these reports do not establish causality and may be related to other factors. The "Safety Score" of 65.0 reflects this limited but generally positive safety data, while acknowledging the lack of extensive clinical trials.

Semax is currently unregulated in many jurisdictions, including the United States. It is not FDA-approved for any specific indication and is not subject to compounding restrictions. This unregulated status places the onus on consumers to exercise caution and source Semax from reputable suppliers, ensuring product purity and quality.

Anecdotally, Semax is used by individuals seeking cognitive enhancement, improved focus, and neuroprotection. These users often self-administer the peptide based on research findings and anecdotal reports found online. However, the lack of FDA approval and comprehensive clinical trials means that the efficacy and long-term safety of Semax for these purposes remain uncertain. The current research landscape and regulatory outlook suggest a need for more rigorous clinical trials to fully understand the potential benefits and risks associated with Semax use.